已发表的部分文献: 标题:MiR-185 mediates lung epithelial cell death after oxidative stress.作者:Zhang D, Lee H, Cao Y, Dela Cruz CS, Jin Y;杂志名称:Am J Physiol Lung Cell Mol Physiol 标题:Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma.作者:Amodio N, Stamato MA, Gullà AM, Morelli E, Romeo E, Raimondi L, Pitari MR, Ferrandino I, Misso G, Caraglia M, Perrotta I, Neri A, Fulciniti M, Rolfo C, Anderson KC, Munshi NC, Tagliaferri P, Tassone P;杂志名称:Mol Cancer Ther 标题:Critical role of SIK3 in mediating high salt and IL-17 synergy leading to breast cancer cell proliferation.作者:Amara S, Majors C, Roy B, Hill S, Rose KL, Myles EL, Tiriveedhi V;杂志名称:PLoS One 标题:Potential anticancer effect of prostratin through SIK3 inhibitio作者:Alotaibi, D., Amara, S., Johnson, T. L., Tiriveedhi, V.";杂志名称:Oncology Letters 标题:Design, Synthesis, In Vitro Anticancer Evaluation and Molecular Modelling Studies of 3,4,5-Trimethoxyphenyl-Based Derivatives as Dual EGFR/HDAC Hybrid Inhibitors.作者:Ibrahim TS, Malebari AM, Mohamed MFA;杂志名称:Pharmaceuticals (Basel) Epigentek 公司是全球领先的表观遗传学相关研究的技术创新者和产品开发供应商。开发了超过700多个专利产品,为表观遗传学方面的研究和新药研发提供全面系统的解决方案,涵盖样品制备、DNA/RNA甲基化(5-mc, 5-hmc, 5-fc, m6A)/DNMT分析、ChIP、组蛋白甲基化/乙酰化/去乙酰化/磷酸化/SUMO-等领域,提供小分子抑制剂、蛋白质、抗体、以及分析试剂盒产品。